Cell Therapy Catapult Limited

This project will develop a new **AI-based anomaly-detection and data-assurance framework** to improve how cleanroom manufacturing environments are monitored and managed. The work is a collaboration between **Decision Lab**, a UK specialist in digital decision intelligence, and the **Cell and Gene Therapy Catapult (CGTC)**, which operates advanced biomanu...

The **S**mart **P**ersonalised **H**ealthcare: **E**valuation, **R**esponse and **E**ngagement (**SPHERE**) is a UK-wide collaboration led by the Catapult Network that aims to make personalised and preventative healthcare a practical reality for everyone. The vision: _"A healthcare system where every individual receives the right diagnosis, the right trea...

Advancements in CGTs for cancer and other high-prevalence conditions are set to transform modern medicine. However, scientific development is outpacing our manufacturing ability to produce these therapies at required scales to reach tens of thousands, let alone millions of eligible patients a year. Current global production (<11,000 therapies/year in 2023...

**Public Description** **A regenerative medicine for vascular disease** VascVersa is developing a groundbreaking cell therapy known as Angicyte, designed to treat vascular ischaemic diseases, which are conditions caused by insufficient blood supply to tissues. Angicyte works by stimulating the formation of new blood vessels in areas with low oxygen levels...

Advanced Therapy Medicinal Products (ATMP) are innovative therapies with potential to cure, rather than ameliorate, diseases addressing significant unmet needs. The ATMP field is rapidly evolving and growing, with a strong global preclinical and clinical pipeline that's broadening from rare to higher prevalence indications and a wave of approvals anticipa...

This project is focused on advancing **sustainable medicines manufacturing** by developing a cutting-edge **stable cell line** system to improve the production of adeno-associated virus (AAV), a key component in gene therapies. Current AAV production methods are costly and inefficient, particularly when scaling up to meet commercial demand. Our solution a...

CAR T cell therapy is a new kind of treatment for cancer and autoimmune disorders. To manufacture CAR T cell therapeutics, white blood cells are harvested from a patient's blood, genetically modified in a specialized manufacturing facility and frozen ready to be administered back to the patient. Because of immune rejection, attempts at mass-production "of...

Metastatic (stage 4) colorectal cancer (mCRC) is an almost uniformly lethal disease with only a 14% 5-year survival rate. Current treatment strategies for mCRC are limited and escape form therapeutic control is common. Development of new treatment strategies is therefore imperative. Oncolytic viruses (OVs) are attractive therapeutics for cancer as they no...

The partnership between CGTC, CPI and Cogent will complement RESILIENCE initiatives and will enhance skills and training opportunities by addressing the gaps and needs of emerging medicines modalities. Creating new training resources coving advanced nucleic acid therapeutics manufacturing will complement existing medicines manufacturing training. This exp...